Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Barclays PLC filed an amended Schedule 13G/A reporting beneficial ownership of 263,695 shares of Phibro Animal Health Corp-A common stock, representing 1.27% of the class. The filing shows Barclays has sole voting and sole dispositive power over the reported shares. The amendment is signed by a Barclays director on 05/14/2026.
Phibro Animal Health insider-related entity BFI Co., LLC sold a net 18,608 shares of Class A Common Stock in open-market transactions from May 5–7, 2026, at weighted average prices ranging from about $47 to $58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. BFI now holds 56,152 shares indirectly associated with President and CEO Jack Bendheim, who also directly holds 16,840 shares and disclaims beneficial ownership of BFI’s holdings beyond his pecuniary interest.
Phibro Animal Health Corporation reported solid growth for its third quarter ended March 31, 2026. Net sales were $383.5 million, up 10% from a year earlier, driven mainly by a 13% increase in Animal Health revenue to $291.2 million. Net income rose to $24.0 million, a 15% increase, and diluted EPS grew 16% to $0.59. Adjusted EBITDA was $60.8 million, up 11%, while adjusted net income reached $31.2 million and adjusted diluted EPS climbed 19% to $0.76.
Gross margin improved to 32.8% from 30.1%, reflecting higher volume, favorable mix and pricing. The company updated fiscal 2026 guidance to net sales of $1.46–$1.50 billion and adjusted EBITDA of $247–$255 million, noting higher midpoints across key measures. Phibro also highlighted a regulatory development in Brazil affecting certain antimicrobial products, a $125 million increase in its revolving credit facility to $435 million, and the launch of its Sustainable Solutions Platform, including VERRATAIN Verified Sustainability Solutions.
Phibro Animal Health delivered higher Q3 2026 results, with net sales of $383.5 million, up 10% from $347.8 million, and net income of $24.0 million versus $20.9 million. Diluted EPS rose to $0.59 from $0.51.
For the nine months, net sales climbed to $1.12 billion, up 22%, while net income more than doubled to $78.0 million, driven largely by the October 2024 Zoetis portfolio acquisition and strong Animal Health growth. Animal Health revenue reached $864.7 million, up 29%, led by medicated feed additives.
Leverage remains meaningful, with term loans of about $625.9 million and revolver borrowings of $115.0 million, pushing interest expense, net, to $34.2 million for the nine months. The company highlights geopolitical exposure in Israel and regulatory risks around carbadox in the U.S. and antimicrobial growth promoters in Brazil.
Phibro Animal Health Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share. The dividend applies to both its Class A and Class B common stock. It will be paid on June 24, 2026 to stockholders of record as of the close of business on June 3, 2026.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on April 28–30, 2026. The weighted average sale prices ranged from about $52.65 to $56.69 per share, with all sales executed under a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. Following these sales, BFI’s reported indirect holdings were 74,760 shares, and Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corporation entered into Amendment No. 1 to its Credit Agreement with Coöperatieve Rabobank U.A. and other lenders on April 28, 2026. This amendment increases the company’s revolving credit commitment by $125,000,000, raising the facility from $310,000,000 to an aggregate commitment of $435,000,000.
The larger revolving credit line represents a new direct financial obligation for Phibro and is documented as a material definitive agreement. The full text of Amendment No. 1 is filed as Exhibit 10.1 and is incorporated by reference for detailed terms, representations and warranties.
Phibro Animal Health Corp reports institutional ownership disclosure. Vanguard Capital Management reports beneficial ownership of 1,043,822 shares, representing 5.06% of common stock as of 03/31/2026. The filing attributes 152,539 shares of sole voting power and 1,043,822 shares of sole dispositive power to Vanguard Capital Management and affiliated business divisions.
Phibro Animal Health Corporation describes a new Brazilian rule that will phase out growth-promotion uses of certain antimicrobial feed additives, including its virginiamycin and bacitracin products. Brazil’s Ministry of Agriculture and Livestock published Ordinance No. 1617, which bans the import, manufacture, marketing and use of these performance-enhancing additives.
The prohibition takes effect after a 180-day transition period, during which current products and labels may still be used and sold. Phibro is pursuing new registrations of virginiamycin for therapeutic use in cattle and broiler chickens and notes its bacitracin product already has therapeutic claims in Brazil. Under the new framework, future use of these antimicrobials will require a veterinary prescription, and Phibro is introducing its PhibroVet digital platform in Brazil to help manage prescriptions. The company expects this regulatory change to have limited impact on its fiscal year 2026 results and plans to provide further detail on its May 7, 2026 earnings call.
BFI Co., LLC and Jack C. Bendheim report updated ownership of Phibro Animal Health Corporation Class A Common Stock in an Amendment No. 24 to Schedule 13D. They beneficially own 19,591,914 shares of Common Stock, representing 48.3% of the Class A Common Stock on an as-converted basis.
BFI directly holds 95,880 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock, which is convertible into Class A on a one-for-one basis and carries ten votes per share. The filing notes market disposals of Class A shares within the prior 60 days, detailed in an exhibit.